mCRPC VL

PSMA Antibody Drug Conjugate in Taxane-treated mCRPC

Details
PSMA Antibody Drug Conjugate in Taxane-treated mCRPC - EAU 2014 Daniel P. Petrylak, MD Click HERE to view the poster from this session

Sequencing Therapy in Advanced PCa: Focus on Sip-T

Details
Sequencing Therapy in Advanced PCa: Focus on Sipuleucel-T Tomasz Beer, MD discusses the sequencing of sipuleucel-T therapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Tomasz M. Beer, MD Oregon Health & Science University Click HERE to read the abstract

Treatment of Progressing mCRPC

Details
Treatment of Progressing mCRPC Alicia Morgans, MD reviews the AUA clinical guideline for the treatment of patients with castration-resistant prostate cancer. Alicia K. Morgans, MD Vanderbilt University Medical Center

Oral Androgen Receptor Pathway Agents are Changing PCa+ Treatment

Details
Oral AR Pathway Agents are Changing Prostate Cancer Treatment New theories for castration-resistant prostate cancer have led to the development of new oral androgen receptor pathway agents. In this presentation, Leonard Gomella, MD focuses on two of these agents – abiraterone acetate and enzalutamide. He presents recent data from the registration trials of each agent. Leonard G. Gomella, MD, FACS...

Androgen Resistance - The Dream Team Research

Details
Clinical Approaches to Androgen Resistance Charles Ryan, MD presents clinical approaches to resistance to therapies that target androgen receptors. Charles J. Ryan, MD Professor of Clinical Medicine Division of Hematology / Oncology Helen Diller Family Comprehensive Cancer Center University of California, San Francisco BIOGRAPHY Charles J. Ryan, MD is a Professor of Medicine in the Division of Hem...

mCRPC PRO

Details
mCRPC PRO Charles Ryan, MD summarizes The Lancet article, Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with mCRPC: patient-reported outcome results of a randomised phase 3 trial , from November 2013. Charles J. Ryan, MD Professor of Clinical Medicine Division of Hematology / Oncology Helen Diller Family Comprehensive Cancer Center University of California,...

Abiraterone Acetate: Evolving Treatment for Metastatic CRPC

Details
Abiraterone Acetate: Evolving Treatment for Metastatic CRPC Paul Sieber, MD reviews an advanced prostate cancer patient case. Paul R. Sieber, MD, FACS Lancaster Urology

PSA Changes as a Surrogate for OS in Men with mCRPC

Details
PSA Changes as a Surrogate for OS in Men with mCRPC Andrew Armstrong, MD summarizes a Journal of Clinical Oncology article, PSA Changes as Surrogate for Overall Survival in Men with mCRPC Treated with Second-line Chemotherapy , from November 2013. Andrew J. Armstrong, MD Duke University School of Medicine Click HERE to read the abstract

The Changing Role of the Urologist

Details
Improving Survival in Advanced Prostate Cancer: The Changing Role of the Urologist E. David Crawford, MD University of Colorado Health Science Center

Treatment of mCRPC Pre-chemotherapy

Details
Updated Interim Analysis (55% OS) of COU-AA-302, a Randomized Phase III Study of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients without Prior Chemotherapy Charles J. Ryan, MD Professor of Clinical Medicine Division of Hematology / Oncology Helen Diller Family Comprehensive Cancer Center University of California, San Francisco BIOGRAPHY Charles J. Ryan, MD is a Prof...